Fox Chase Cancer Center News

PHILADELPHIA (MARCH 30, 2021)—There’s more and more evidence that genes associated with one type of cancer may increase risk for other cancers as well. Now a study by Fox Chase Cancer Center scientists quantifies new risks for pancreatic, prostate, gastric, and other cancer in a gene previously linked to breast cancer.

PHILADELPHIA (March 29, 2021)—Sameer Patel, MD, FACS, chief of the Division of Plastic and Reconstructive Surgery in the Department of Surgical Oncology at Fox Chase Cancer Center and the Temple University Health System, has co-authored a new textbook, “Cosmetic Breast Surgery.”

PHILADELPHIA (March 29, 2021)—Sameer Patel, MD, FACS, chief of the Division of Plastic and Reconstructive Surgery in the Department of Surgical Oncology at Fox Chase Cancer Center and the Temple University Health System, has co-authored a new textbook, “Cosmetic Breast Surgery.”

PHILADELPHIA (March 26, 2021)—In a recently published study, researchers at Fox Chase Cancer Center found that reprogramming cancer-associated fibroblasts that define tumor progression in pancreatic ductal adenocarcinoma could potentially restore the fibroblasts’ ability to work against tumors. Further development of the findings could have applications in the treatment of cancer.

PHILADELPHIA (March 26, 2021)—Fox Chase Cancer Center has begun utilizing a new program called MyCareCompass that is designed to support patients with necessary information about their care by sending that information directly to them.

PHILADELPHIA (March 17, 2021)—In a recent study, researchers at Fox Chase Cancer Center assessed head and neck cancer patients’ satisfaction with the use of a web-based tool designed to provide information and strategies for managing symptom-focused concerns.

PHILADELPHIA (March 16, 2021) — The drug ibrutinib, also known by the brand name Imbruvica, can be an effective tool to slow or stop tumor growth in lymphoma, a type of B-cell neoplasia. But for patients who become resistant to the medication, there are a limited number of other options. Now, new research by Fox Chase Cancer Center physician-scientists opens the door for alternative treatments

PHILADELPHIA (March 12, 2021)—Researchers at Fox Chase Cancer Center recently conducted a study that showed the immunotherapy drug pembrolizumab, also known by the brand name Keytruda, has limited treatment efficacy when used alone in the treatment of high-grade neuroendocrine neoplasms (G3 NENs).